Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm’s…
(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm’s…
By Mike Scarcella (Reuters) – The U.S. Justice Department’s blockbuster case accusing Apple of unlawfully monopolizing the smartphone market was…
By Max A. Cherney SAN FRANCISCO (Reuters) – Meta Platforms unveiled details on Wednesday about the next generation of the…
By Medha Singh (Reuters) – Retail traders are piling into risky bets after recouping all the losses made in the…
By Max A. Cherney SAN FRANCISCO (Reuters) – Google on Tuesday revealed the details of a new version of its…
By Sarah N. Lynch and Makini Brice WASHINGTON (Reuters) -The U.S. Justice Department on Monday rebuffed demands by Republicans in…
By Abhirup Roy and Aditya Soni (Reuters) -Tesla has settled a lawsuit over a 2018 car crash that killed an…
By Kanishka Singh WASHINGTON (Reuters) -Representative Nancy Pelosi, former House speaker and a key ally of Joe Biden, signed a…
By David Shepardson WASHINGTON (Reuters) -United Airlines said on Monday it has delayed the start of two new international routes,…
By Lewis Krauskopf NEW YORK (Reuters) – Recent action in the U.S. stock market suggests investors are beginning to price…